Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Pulmonary Arterial Hypertension
NCT03251872Phase 1Terminated
- Sponsor
- Université Laval
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in pulmonary arterial hypertension (PAH), sponsored by Université Laval. Primary endpoint: Change in pulmonary vascular resistance at 16 weeks. Started Oct 2018; status: terminated.
02
Drugs
olaparib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03251872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251872.